Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Healthcare Policy topic
No spam. Unsubscribe anytime.
Bill to make collaborative drug-therapy agreements confidential divides providers and media advocates
Summary
House Bill 2,176 would exempt collaborative drug therapy agreements (CDTAs) from public disclosure except when the agreement is the basis for disciplinary action; supporters say confidentiality protects providers (including those prescribing medication abortion or gender-affirming care), while journalists and open-government groups warn about reduced transparency of clinical arrangements.
OPR staff summarized House Bill 2,176 as a narrowly targeted change: CDTAs (agreements setting a pharmacist's prescriptive authority under supervision or protocols) would be confidential under the Public Records Act except where the CDTA forms the basis of an order, stipulation or disciplinary action. Disclosed CDTAs in disciplinary cases must have personal information redacted for persons who are not the subject of the disciplinary action.
Representative Mylene Tai (41st District), the bill sponsor, said CDTAs are longstanding clinical tools that increase access to care and argued confidentiality is needed to protect providers and their patients without undermining accountability when misconduct occurs. Dr. Crystal Beal, a practicing family-medicine physician and clinical instructor at the University of Washington, described receiving death threats and said public exposure of agreements has been used to intimidate clinicians out of practice. Don Downing (Professor Emeritus, UW School of Pharmacy) and Beth Rubin (Uplift International) also testified that threats following PRA requests for CDTA materials had chilled participation in innovative pharmacy-led programs, including medication abortion provision.
Media and broadcaster representatives, and the Allied Daily Newspapers and Washington State Association of Broadcasters, urged caution. Roland Thompson told the committee CDTAs are "private, contractual agreements" and that the news business cares about the regulator's actions; he said the public interest is in the actions of the agency rather than the private identities of providers, and raised concerns about administrative opacity if too much material is made confidential.
Staff and witnesses discussed operational safeguards and the limited exception: a CDTA would be available for public inspection where it served as the basis for disciplinary action, with redaction of unrelated personal data. Several supporters said the agreement content (protocols and non-identifying practice information) can often be made available while protecting provider names. The committee posed clarifying questions about how redactions would be handled and whether copies are available at pharmacies or prescribing offices; the sponsor and witnesses said copies and redacted protocols remain accessible in appropriate circumstances.
No committee vote was taken; staff said further clarification and technical drafting work may be needed.
